Application of Liposomes in Non-Viral Vectors

With the development of pathology, the traditional way of drug delivery is gradually unable to meet the needs of increasingly complex cancers, genetic diseases, and other drug delivery needs, so gene delivery was born. Precise, efficient delivery reduces damage to normal cells, improves treatment effect, and reduces the amount of drug used, hence the growing academic interest in gene delivery. To design more efficient and less harmful delivery vectors, non-viral vectors are gradually replacing the traditional viral vectors. As the most advanced non-viral vectors, lipid nanoparticles (LNPs) are widely used, such as Pfizer's COVID-19 vaccine —— a vaccine with a prevention efficacy of up to 75% was designed within a short research and development cycle. This article will summarize the existing information on LNPs as non-viral vectors, including delivery processes, target recognition, existing drawbacks, etc., to find vector designs with higher delivery efficiency, lower toxicity, and more generalizability.